Abstract 1795P
Background
In the global ARCHES trial (NCT02677896), ENZA + ADT improved overall survival and radiographic progression-free survival (rPFS) vs PBO + ADT in pts with mHSPC. The China ARCHES trial evaluated the efficacy and safety of ENZA + ADT vs PBO + ADT in Chinese pts with mHSPC.
Methods
Chinese men with mHSPC (positive bone scan or CT scan) were randomized 2:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratified by disease volume and prior docetaxel therapy. Treatment continued until intolerability or confirmed radiographic progression. The primary endpoint was time to prostate-specific antigen (PSA) progression (TTPP; PSA progression defined as ≥25% increase and absolute increase of ≥2 ng/mL above the nadir, confirmed after ≥3 weeks), based on central laboratory test. Selected secondary endpoints included rPFS, time to castration resistance (TTCR), PSA undetectable (<0.2 ng/mL) rate in patients with detectable PSA at baseline, and safety. We report the results of a prespecified interim analysis (63 TTPP events accrued).
Results
At data cut-off (November 18, 2022), 180 pts (ENZA + ADT, n=120; PBO + ADT, n=60) had been randomized from 27 centers in China (median age, 68.5 years). Baseline characteristics were balanced between treatment arms. Median treatment duration with ENZA + ADT vs PBO + ADT was 25.66 vs 15.11 months. Based on 63 centrally confirmed PSA progressions (ENZA + ADT, 23; PBO + ADT, 40), ENZA + ADT significantly reduced the risk of PSA progression by 87% vs PBO + ADT (Table). rPFS, TTCR, and PSA undetectable rate were among the secondary endpoints improved with ENZA + ADT vs PBO + ADT. Safety outcomes in pts from China were consistent with those in the global ARCHES population. Table: 1795P
Endpoint | ENZA + ADT N=120 | PBO + ADT N=60 | Hazard ratioa (95% CI) | p value |
TTPPb (95% CI)c | NR (NR, NR) | 9.2 (6.54, 17.48) | 0.13 (0.076, 0.222) | <0.0001d |
rPFSb (95% CI)c | NR (28.25, NR) | 19.4 (13.63, NR) | 0.33 (0.196, 0.556) | <0.0001d,e |
TTCRb (95% CI)c | NR (31.18, NR) | 8.3 (6.41, 14.69) | 0.172 (0.107, 0.276) | <0.0001d,e |
PSA undetectable, % (95% CI)f | 76.3 (67.4, 83.8) | 22.8 (12.7, 35.8) | <0.0001e,g |
aCox proportional hazards modelh bMedian months: Kaplan-Meier method cBrookmeyer and Crowley method dLog-rank testh eNominal p value fClopper-Pearson method based on exact binomial distribution gCochran-Mantel-Haenszel score testh hStratified model/test CI=confidence interval; N=no. of randomized pts; NR=not reached.
Conclusions
Efficacy and safety results in China ARCHES were generally consistent with those in the global ARCHES trial.
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial assistance were provided by Marietou Daou, MSc, and Jane Beck, MA, from Complete HealthVizion, IPG Health Medical Communications, funded by the study sponsors.
Legal entity responsible for the study
Astellas Pharma Inc.; Pfizer Inc.
Funding
This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide.
Disclosure
F. Zhou, Z. Gongqian, H. Guo, Z. Hu, D. He, D. Zhang, Y. Li, H. Kadeerbai, Y. Liu, D. Ye: Non-Financial Interests, Institutional, Other, Study funding and support for Medical Writing/editing: Astellas; Non-Financial Interests, Institutional, Other, Medical writing/editing support: Complete HealthVizion. X. Zhang, Z. He: Non-Financial Interests, Institutional, Writing Engagement: Astellas Pharma Inc.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14